Amgen's KRAS-targeting drug showed strong results, but it's pricey
(Newser) -
Chemotherapy, known as much for its toxic side effects as its cancer-fighting prowess, may have some serious competition. Per the Wall Street Journal, biopharma giant Amgen released significant new data from a study of Lumakras, which last year became the first drug of its kind to gain FDA approval. The...